101
|
Goel S, Sachdev R, Gajendra S, Jha B, Sahni T, Dorwal P, Srivastava C, Tiwari AK, Sood N, Gupta S, Raina V, Vaid AK. Picking up myelodysplastic syndromes and megaloblastic anemias on peripheral blood: use of NEUT-X and NEUT-Y in guiding smear reviews. Int J Lab Hematol 2014; 37:e48-51. [PMID: 25132616 DOI: 10.1111/ijlh.12285] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- S. Goel
- Departments of Pathology; Lab Medicine and Transfusion Medicine; Medanta - The Medicity Hospital; Gurgaon India
| | - R. Sachdev
- Departments of Pathology; Lab Medicine and Transfusion Medicine; Medanta - The Medicity Hospital; Gurgaon India
| | - S. Gajendra
- Departments of Pathology; Lab Medicine and Transfusion Medicine; Medanta - The Medicity Hospital; Gurgaon India
| | - B. Jha
- Departments of Pathology; Lab Medicine and Transfusion Medicine; Medanta - The Medicity Hospital; Gurgaon India
| | - T. Sahni
- Departments of Pathology; Lab Medicine and Transfusion Medicine; Medanta - The Medicity Hospital; Gurgaon India
| | - P. Dorwal
- Departments of Pathology; Lab Medicine and Transfusion Medicine; Medanta - The Medicity Hospital; Gurgaon India
| | - C. Srivastava
- Departments of Pathology; Lab Medicine and Transfusion Medicine; Medanta - The Medicity Hospital; Gurgaon India
| | - A. K. Tiwari
- Departments of Pathology; Lab Medicine and Transfusion Medicine; Medanta - The Medicity Hospital; Gurgaon India
| | - N. Sood
- Department of Medical Oncology and Hematology; Medanta - The Medicity Hospital; Gurgaon India
| | - S. Gupta
- Department of Medical Oncology and Hematology; Medanta - The Medicity Hospital; Gurgaon India
| | - V. Raina
- Departments of Pathology; Lab Medicine and Transfusion Medicine; Medanta - The Medicity Hospital; Gurgaon India
| | - A. K. Vaid
- Department of Medical Oncology and Hematology; Medanta - The Medicity Hospital; Gurgaon India
| |
Collapse
|
102
|
Bair-Merritt MH, Lewis-O'Connor A, Goel S, Amato P, Ismailji T, Jelley M, Lenahan P, Cronholm P. Primary care-based interventions for intimate partner violence: a systematic review. Am J Prev Med 2014; 46:188-94. [PMID: 24439354 DOI: 10.1016/j.amepre.2013.10.001] [Citation(s) in RCA: 101] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2013] [Revised: 07/22/2013] [Accepted: 10/04/2013] [Indexed: 12/23/2022]
Abstract
CONTEXT Primary care providers are uniquely positioned to respond to patients' disclosure of intimate partner violence (IPV). However, the research on primary care-based IPV interventions has not been systematically synthesized, making it difficult for providers, policymakers, and researchers to understand how to effectively intervene in the primary care setting. This systematic review summarizes primary care-based interventions for patients experiencing IPV. EVIDENCE ACQUISITION PubMed, PsycINFO, and CINAHL were searched from their start through September 2012; this search was augmented by bibliographic review and consultation with experts. Eligible studies included English-language, peer-reviewed articles that assessed patient-level impact of IPV interventions that originated from patients' visits to a primary care provider. EVIDENCE SYNTHESIS Of 80 potentially eligible studies, 17 met eligibility criteria. The majority of interventions recruited women from reproductive care sites. Interventions tended to be brief, delivered by nonphysicians, and focused on empowerment, empathetic listening, discussion of the cycle of violence and safety, and referral to community-based resources. Thirteen studies demonstrated at least one intervention-related benefit. Six of 11 articles measuring IPV persistence found reductions in future violence; two of five measuring safety-promoting behaviors found increases; and six of ten measuring IPV/community resource referrals found enhanced use. Some studies also documented health improvements. CONCLUSIONS The majority of studies demonstrated patient-level benefit subsequent to primary care IPV interventions, with IPV/community referrals the most common positively affected outcome.
Collapse
Affiliation(s)
| | - Annie Lewis-O'Connor
- Center for Women and Newborns, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| | - Swati Goel
- Johns Hopkins University, Baltimore, Maryland
| | - Paula Amato
- Oregon Health and Science University, Portland, Oregon
| | | | - Martina Jelley
- Department of Internal Medicine , University of Oklahoma School of Community Medicine, Tulsa, Oklahoma
| | - Patricia Lenahan
- University of Southern California, School of Social Work, Los Angeles, California
| | - Peter Cronholm
- Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Public Health Initiatives, University of Pennsylvania, Philadelphia, Pennsylvania; Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania
| |
Collapse
|
103
|
Abstract
Context: A growing number of cities, districts, counties and states across the globe are going smoke-free. While an Indian national law namely Cigarettes and Other Tobacco Products Act (COTPA) exists since 2003 and aims at protecting all the people in our country; people still smoke in public places. Aim: This study assessed knowledge and perceptions about smoking, SHS and their support for Smoke-free laws among people residing in Mohali district, Punjab. Materials and Methods: This cross-sectional study was conducted in Mohali district of Punjab, India. A sample size of 1600 people was obtained. Probability Proportional to Size technique was used for selecting the number of individuals to be interviewed from each block and also from urban and rural population. Statistical Analysis Used: We estimated proportions and tested for significant differences by residence, smoking status, literacy level and employment level by means of the chi-square statistics. Statistical software SPSS for Windows version 20 was used for analysing data . Results: The overall prevalence of current smoking among study participants was 25%. Around 96% were aware of the fact that smoking is harmful to health, 45% viewed second-hand smoke to be equally harmful as active smoking, 84.2% knew that smoking is prohibited in public places and 88.3% wanted the government to take strict actions to control the menace of public smoking. Multivariate logistic regression analysis showed that people aged 20 years and above, unemployed, urban, literate and non-smokers had significantly better perception towards harms of smoking. The knowledge about smoke free provisions of COTPA was significantly better among males, employed individuals, urban residents, and literate people. Conclusions: There was high knowledge about deleterious multi-dimensional effects of smoking among residents and a high support for implementation of COTPA. Efforts should be taken to make Mohali a "smoke-free district".
Collapse
Affiliation(s)
- S Goel
- School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, India
| | | | | | | |
Collapse
|
104
|
Gupta S, Kamarthi N, Keswani T, Venkatraman S, Goel S, Goel S. Assessment of the attitude of undergraduate dental students toward the geriatric population. ACTA ACUST UNITED AC 2014. [DOI: 10.4103/1119-0388.140428] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
105
|
Goel S, Kumar R, Lal P, Sharma D, Singh RJ. Refining compliance surveys to measure the smokefree status of jurisdictions using the Delphi method. Public Health Action 2013; 3:342-5. [PMID: 26393059 PMCID: PMC4463165 DOI: 10.5588/pha.13.0063] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2013] [Accepted: 10/22/2013] [Indexed: 11/10/2022] Open
Abstract
SETTING Compliance assessment surveys are cost-effective means of assessing smokefree status in a jurisdiction. Assigning weights to assessment criteria (indicators) can also inform law implementers and policy makers about the effectiveness of the enforcement of smokefree rules. OBJECTIVE To develop a standardised measure for compliance surveys using the Delphi method in India. DESIGN Tobacco control experts from India comprising different constituencies and jurisdictions met for a half-day workshop in August 2012 to deliberate on how weights can be assigned to criteria for smokefree status. Using the Delphi method, the relevance and ranking of criteria from an existing protocol for measuring compliance was evaluated. RESULTS Consensus was reached on all five compliance survey indicators through three rigorous rounds of discussion. The highest priority was assigned to the absence of the act of smoking in public places (33%), followed by the display of no-smoking signage in public places (32%), absence of cigarette butts or bidi stubs (15%), absence of smoking aids (10%) and absence of tobacco smoke and ash (10%). CONCLUSION Tobacco control advocates can effectively inform local policy makers using weights that prioritise directed enforcement and targeted interventions, which in turn will ensure stronger compliance and sustainable smokefree settings.
Collapse
Affiliation(s)
- S Goel
- School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - R Kumar
- International Union Against Tuberculosis and Lung Disease South-East Asia Regional Office, New Delhi, India
| | - P Lal
- International Union Against Tuberculosis and Lung Disease South-East Asia Regional Office, New Delhi, India
| | - D Sharma
- School of Public Health, Postgraduate Institute of Medical Education and Research, Chandigarh, India
| | - R J Singh
- International Union Against Tuberculosis and Lung Disease South-East Asia Regional Office, New Delhi, India
| |
Collapse
|
106
|
Goel S. Bronchopleural Fistula Mimicking Chronic Obstructive Lung Disease on 133Xe Scan. J Nucl Med Technol 2013; 41:236-7; 241-2. [DOI: 10.2967/jnmt.113.126425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
107
|
Fogli LK, Sundrud MS, Goel S, Bajwa S, Jensen K, Derudder E, Sun A, Coffre M, Uyttenhove C, Van Snick J, Schmidt-Supprian M, Rao A, Grunig G, Durbin J, Casola S, Casola SS, Rajewsky K, Koralov SB. T cell-derived IL-17 mediates epithelial changes in the airway and drives pulmonary neutrophilia. J Immunol 2013; 191:3100-11. [PMID: 23966625 DOI: 10.4049/jimmunol.1301360] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Th17 cells are a proinflammatory subset of effector T cells that have been implicated in the pathogenesis of asthma. Their production of the cytokine IL-17 is known to induce local recruitment of neutrophils, but the direct impact of IL-17 on the lung epithelium is poorly understood. In this study, we describe a novel mouse model of spontaneous IL-17-driven lung inflammation that exhibits many similarities to asthma in humans. We have found that STAT3 hyperactivity in T lymphocytes causes an expansion of Th17 cells, which home preferentially to the lungs. IL-17 secretion then leads to neutrophil infiltration and lung epithelial changes, in turn leading to a chronic inflammatory state with increased mucus production and decreased lung function. We used this model to investigate the effects of IL-17 activity on airway epithelium and identified CXCL5 and MIP-2 as important factors in neutrophil recruitment. The neutralization of IL-17 greatly reduces pulmonary neutrophilia, underscoring a key role for IL-17 in promoting chronic airway inflammation. These findings emphasize the role of IL-17 in mediating neutrophil-driven pulmonary inflammation and highlight a new mouse model that may be used for the development of novel therapies targeting Th17 cells in asthma and other chronic pulmonary diseases.
Collapse
Affiliation(s)
- Laura K Fogli
- Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
108
|
Abstract
Carfilzomib is a second-generation selective proteasome inhibitor that has been recently approved in the use for refractory multiple myeloma. It has been shown to be beneficial in both bortezomib-resistant and bortezomib-naive patients, with a tolerable side effect profile. Peripheral neuropathy is less common in patients receiving carfilzomib compared to bortezomib. Recent and ongoing clinical trials are establishing the role of carfilzomib in the treatment of refractory multiple myeloma.
Collapse
Affiliation(s)
- J Lue
- New York University Langone Medical Center, New York, NY, USA
| | | | | |
Collapse
|
109
|
Cox KM, Goel S, O'Connell RL, Boyer M, Beale PJ, Simes RJ, Stockler MR. Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin. Intern Med J 2013; 41:172-8. [PMID: 20214694 DOI: 10.1111/j.1445-5994.2010.02201.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND/AIMS Treatment with high-dose cisplatin (HDC) previously required inpatient (IP) admission with overnight hospitalization, but recently practice has shifted to outpatient (OP) therapy. We aimed to determine whether it is preferable to give HDC as an IP or OP using a two-period cross-over trial. METHODS Eligible patients were starting chemotherapy with ≥2 cycles of HDC (≥100 mg/dose) and were suitable for OP treatment. All patients received an IP cycle and OP cycle: the order was randomly allocated. Pre-hydration, anti-emetics and chemotherapy were identical for IP and OP. Post-hydration varied by group (3 L normal saline (NS) for IP, 2 L NS for OP). The primary outcome was patient preference for IP versus OP treatment. Secondary outcomes included aspects of health-related quality of life, adverse events (dose delays and reductions, elevated creatinine and unplanned readmissions) and resource use. RESULTS Fifty-nine patients were randomized, 53 completed two cycles of HDC. Most patients preferred OP treatment (36 vs 13, P = 0.002). There were no significant differences in patients' ratings of nausea, vomiting, fatigue, anxiety, depression or overall quality of life. Adverse events were few and unrelated to IP versus OP treatment. Nursing time was longer for IP than OP (163 vs 104 min, P < 0.001). CONCLUSION OP treatment was preferred by most patients, appeared safe and used less resources.
Collapse
Affiliation(s)
- K M Cox
- Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
| | | | | | | | | | | | | |
Collapse
|
110
|
|
111
|
Kodack DP, Chung E, Yamashita H, Incio J, Peters A, Song Y, Ager E, Huang Y, Farrar C, Lussiez A, Goel S, Snuderl M, Kamoun W, Hiddingh L, Tannous BA, Fukumura D, Engelman JA, Jain RK. Abstract P3-12-03: Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-12-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Brain metastases remain a serious obstacle in the treatment of patients with human epidermal growth factor receptor-2 (HER2)-amplified breast cancer. Unlike HER2-amplified breast tumors growing in extra-cranial locations, brain metastases do not respond well to HER2 inhibitors and are often the reason for treatment failure. One of the major challenges in studying brain metastases is the lack of preclinical models. We developed a HER2-amplified mouse model of brain metastasis using an orthotopic xenograft of BT474 cells in mice. As seen in patients, the HER2 inhibitors trastuzumab and lapatinib failed to contain brain metastatic tumor growth.
Based on previous findings from our laboratory suggesting a role of vascular endothelial growth factor (VEGF) in the resistance of HER2-overexpressing breast cancer brain metastases to trastuzumab, we combined HER2 inhibitors with the anti-VEGFR2 antibody DC101. The combination of either trastuzumab and DC101 or lapatinib and DC101 significantly slowed metastatic tumor growth in the brain, and resulted in a striking improvement in overall survival. The benefit is due largely to an anti-angiogenic effect. The combination of anti-HER2 and anti-VEGFR2 therapy reduced both the total and functional microvascular density in the brain metastatic tumors. Moreover, tumor tissues under combination therapy showed a marked increase in necrosis.
Preclinical and clinical evidence suggest that the combination of trastuzumab and lapatinib is superior to either agent alone – though this has never been tested in the brain metastatic setting. We consistently observed increased phosphorylation of HER2 in breast tumor cells growing in the brain compared with the mammary fat pad. In addition, while short-term lapatinib treatment significantly reduced HER2 activation in the brain, it could do so only to the level of that observed in the untreated mammary fat pad - and this effect disappeared over time. We hypothesized that more pronounced HER2 inhibition would be beneficial to these brain metastases with increased HER2 activation. We show here a significant growth delay with the combination of the two HER2 inhibitors compared with monotherapy. Moreover, we found a dramatic brain metastatic tumor growth delay in mice treated with both HER2 inhibitors, trastuzumab and lapatinib, and DC101. The triple combination prolonged overall survival 5 times longer than control-treated mice.
Brain metastasis from breast cancer is considered the “final frontier” of breast cancer research and treatment. Our findings support the clinical development of a three-drug regimen of trastuzumab, lapatinib and a VEGF pathway inhibitor for the treatment of HER2-amplified breast cancer brain metastases. While the anti-VEGF antibody bevacizumab in combination with trastuzumab and chemotherapy has shown some promise in HER2-positive metastatic breast cancer patient, there are no data on its efficacy in the context of brain metastases. A clinical trial is now recruiting patients to evaluate the efficacy of bevacizumab in breast cancer patients with active brain metastases, including its combination with trastuzumab in patients with HER2-positive disease. This trial may provide clinical evidence for the approach presented here.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-12-03.
Collapse
Affiliation(s)
- DP Kodack
- Massachusetts General Hospital, Boston, MA
| | - E Chung
- Massachusetts General Hospital, Boston, MA
| | | | - J Incio
- Massachusetts General Hospital, Boston, MA
| | - A Peters
- Massachusetts General Hospital, Boston, MA
| | - Y Song
- Massachusetts General Hospital, Boston, MA
| | - E Ager
- Massachusetts General Hospital, Boston, MA
| | - Y Huang
- Massachusetts General Hospital, Boston, MA
| | - C Farrar
- Massachusetts General Hospital, Boston, MA
| | - A Lussiez
- Massachusetts General Hospital, Boston, MA
| | - S Goel
- Massachusetts General Hospital, Boston, MA
| | - M Snuderl
- Massachusetts General Hospital, Boston, MA
| | - W Kamoun
- Massachusetts General Hospital, Boston, MA
| | - L Hiddingh
- Massachusetts General Hospital, Boston, MA
| | - BA Tannous
- Massachusetts General Hospital, Boston, MA
| | - D Fukumura
- Massachusetts General Hospital, Boston, MA
| | | | - RK Jain
- Massachusetts General Hospital, Boston, MA
| |
Collapse
|
112
|
Joshi P, Chaudhuri S, Goel M, Goel S. Malignant melanoma of paranasal sinuses with intracranial extension. Indian J Med Spec 2012. [DOI: 10.7713/ijms.2012.0083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
113
|
Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol 2012; 23:1234-1240. [PMID: 21930687 PMCID: PMC3945398 DOI: 10.1093/annonc/mdr399] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2011] [Revised: 07/13/2011] [Accepted: 07/18/2011] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND This multicenter phase II trial evaluated the efficacy and safety of trabectedin in metastatic castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS Two schedules were evaluated in three cohorts: weekly as 3-h i.v. infusion at 0.58 mg/m(2) for 3 out of 4 weeks (Cohort A, n = 33), and every 3 weeks (q3wk) as 24-h infusion at 1.5 mg/m(2) (Cohort B1, n = 5) and 1.2 mg/m(2) (Cohort B2, n = 20). The primary end point was prostate-specific antigen (PSA) response; secondary end points included safety, tolerability and time to progression (TTP). RESULTS Trabectedin resulted in PSA declines ≥ 50% in 12.5% (Cohort A) and 10.5% (Cohort B2) of patients. Among men pretreated with taxane-based chemotherapy, PSA response was 13.6% (Cohort A) and 15.4% (Cohort B2). PSA responses lasted 4.1-8.6 months, and median TTP was 1.5 months (Cohort A) and 1.9 months (Cohort B2). The dose of 1.5 mg/m(2) (approved for soft tissue sarcoma) given as 24-h infusion q3wk was not tolerable in these patients. At 1.2 mg/m(2) q3wk and 0.58 mg/m(2) weekly, the most common adverse events were nausea, fatigue and transient neutropenia and transaminase increase. CONCLUSIONS Two different trabectedin schedules showed modest activity in metastatic CRPC. Further studies may require identification of predictive factors of response in prostate cancer.
Collapse
Affiliation(s)
- M D Michaelson
- Massachusetts General Hospital Cancer Center, Boston, USA.
| | - J Bellmunt
- Medical Oncology Service, Hospital del Mar, Barcelona, Spain
| | - G R Hudes
- Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia
| | - S Goel
- Department of Oncology, Montefiore-Einstein Cancer Center, Bronx
| | - R J Lee
- Massachusetts General Hospital Cancer Center, Boston, USA
| | - P W Kantoff
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | - C A Stein
- Department of Oncology, Montefiore-Einstein Cancer Center, Bronx
| | - P Lardelli
- Clinical R&D, PharmaMar, Colmenar Viejo, Madrid, Spain
| | - I Pardos
- Clinical R&D, PharmaMar, Colmenar Viejo, Madrid, Spain
| | - C Kahatt
- Clinical R&D, PharmaMar, Colmenar Viejo, Madrid, Spain
| | - A Nieto
- Clinical R&D, PharmaMar, Colmenar Viejo, Madrid, Spain
| | | | - N L Lewis
- Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia
| | - M R Smith
- Massachusetts General Hospital Cancer Center, Boston, USA
| |
Collapse
|
114
|
Hou J, Isani S, Ghalib M, Swami U, Goldberg G, Goel S. Patients with gynecologic malignancies on phase I clinical trials: A single institutional experience from 1999 to 2010. Gynecol Oncol 2012. [DOI: 10.1016/j.ygyno.2011.12.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
115
|
Hong H, Goel S, Zhang Y, Cai W. Molecular imaging with nucleic acid aptamers. Curr Med Chem 2012; 18:4195-205. [PMID: 21838686 DOI: 10.2174/092986711797189691] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2011] [Revised: 06/22/2011] [Accepted: 06/22/2011] [Indexed: 01/16/2023]
Abstract
With many desirable properties such as ease of synthesis, small size, lack of immunogenicity, and versatile chemistry, aptamers represent a class of targeting ligands that possess tremendous potential in molecular imaging applications. Non-invasive imaging of various disease markers with aptamer-based probes has many potential clinical applications such as lesion detection, patient stratification, treatment monitoring, etc. In this review, we will summarize the current status of molecular imaging with aptamer-based probes. First, fluorescence imaging will be described which include both direct targeting and activatable probes. Next, we discuss molecular magnetic resonance imaging and targeted ultrasound investigations using aptamer-based agents. Radionuclide-based imaging techniques (single-photon emission computed tomography and positron emission tomography) will be summarized as well. In addition, aptamers have also been labeled with various tags for computed tomography, surface plasmon resonance, dark-field light scattering microscopy, transmission electron microscopy, and surface-enhanced Raman spectroscopy imaging. Among all molecular imaging modalities, no single modality is perfect and sufficient to obtain all the necessary information for a particular question. Thus, a multimodality probe has also been constructed for concurrent fluorescence, gamma camera, and magnetic resonance imaging in vivo. Although the future of aptamer-based molecular imaging is becoming increasingly bright and many proof-of-principle studies have already been reported, much future effort needs to be directed towards the development of clinically translatable aptamer-based imaging agents which will eventually benefit patients.
Collapse
Affiliation(s)
- H Hong
- Department of Radiology, University of Wisconsin-Madison, 1111 Highland Ave, Madison, WI 53705-2275, USA
| | | | | | | |
Collapse
|
116
|
Abstract
ABSTRACT
DentaScan is a unique new computer software program which provides computed tomographic (CT) imaging of the mandible and maxilla in three planes of reference: axial, panoramic, and oblique sagittal (or cross-sectional). The clarity and identical scale between the various views permits uniformity of measurements and cross-referencing of anatomic structures through all three planes. Unlike previous imaging techniques, the oblique sagittal view permits the evaluation of distinct buccal and lingual cortical bone margins, as well as clear visualization of internal structures, such as the incisive and inferior alveolar canals.
Collapse
|
117
|
Boysen G, Goel S, Georgieva N. Profiling the internal dose of reactive compounds and their metabolites using N-terminal valine adducts. Toxicol Lett 2011. [DOI: 10.1016/j.toxlet.2011.05.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
118
|
Goel S. S13.2 Assessing respondent-driven sampling. Br J Vener Dis 2011. [DOI: 10.1136/sextrans-2011-050102.53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
119
|
Papanikolaou T, Goel S, Jayamanne DGR, Mudhar H, Desai SP. Authors' response. Br J Ophthalmol 2011. [DOI: 10.1136/bjo.2010.199752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
120
|
Nayak JB, Maitra R, Basu-Mallick A, Sood A, Mariadason J, Reynolds DM, Goel S. High throughput sequencing technology (Sequenom) as a tool to detect SNPs in human metastatic colorectal cancer (mCRC) and cell lines. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
121
|
Tagawa ST, Saran A, Akhtar NH, Goel S, Mileo G, Kung S, Beltran H, Milowsky MI, Mazumdar M, Wright JJ, Nanus DM. Final phase II results of NCI 6981: A phase I/II study of sorafenib (S) plus gemcitabine (GEM) and capecitabine (CAP) for advanced renal cell carcinoma (RCC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
122
|
Ohnuma T, Holland JF, Goel S, Wilck E, Lehrer D, Ghalib MH, Chaudhary I, Wilhelm F, Swami U, Mani S. Final results of a phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e13584] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
123
|
Goel S, Lynch J, Chantrill LA, Rutovitz JJ, Murray B, Abdi EA, Bell R, Sullivan AL, Goldrick A, Hayes TM, Asghari G, Wilcken N, McCarthy NJ, Beith JM. Serum NT pro-BNP and individual genetic polymorphisms as predictors of trastuzumab-related cardiotoxicity. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
124
|
Ghamande SA, Lin C, Cho DC, Coleman TA, Chaudhary I, Cleary JM, Silverman MH, Kuo M, Mach W, Tseng Y, Hsu SC, Goel S. A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388, administered intravenously to patients with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e13618] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
125
|
Sarantopoulos J, Lenz H, LoRusso P, Shibata S, Kummar S, Mulkerin D, Ramanathan RK, Mita MM, O'Rourke P, Remick SC, Goel S, Gutierrez M, Ramalingam SS, Murgo A, Davies AM, Mani S, Boni J, Shapiro M, Ivy SP, Takimoto CH. Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3072] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
126
|
Swami U, Ghalib MH, Chaudhary I, Hou JY, Aparo S, Einstein MH, Goldberg GL, Elrafei TN, Gajavelli S, Cohen B, Rajdev L, Kaubisch A, Haigentz M, Mani S, Goel S. Risks and benefits of phase I trials: Twelve-years experience from a single institution. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.6098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
127
|
Lin C, Ghamande S, Cho D, Silverman M, Fong K, Kuo M, Mach W, Tseng Y, Hsu S, Goel S. 571 TLC388, a novel topoisomerase-1 inhibitor with anti-hypoxia inducible factor-1 alpha activity: a phase I and pharmacokinetic study in patients with advanced solid malignancies. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72278-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
128
|
Papanikolaou T, Goel S, Jayamanne DGR, Mudhar H, Desai SP. Familial pattern of Salzmann-type nodular corneal degeneration--a four generation series. Br J Ophthalmol 2010; 94:1543. [DOI: 10.1136/bjo.2009.177055] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
129
|
Abstract
AIMS Various features have been described in the literature to differentiate benign from malignant lesions. The aim of the present study was to study the accuracy of each of these features and that of magnetic resonance imaging (MRI) in diagnosing malignant lesions. MATERIALS AND METHODS Fifty-five consecutive patients presenting with neoplastic (both benign and malignant) lesions diagnosed clinically and on ultrasound were studied and their MRI features were compared with the findings on surgical exploration and histopathologic examination. RESULTS There were 32 (58%) benign and 23 (42%) malignant masses. Malignant masses were more common in patients older than 20 years (83%), and these had symptoms of less than 6 months duration (75%), as against benign lesions. The swelling was painful in 8 malignant masses and these were more common in the upper limbs (61%). Various features of malignant lesions were size more than 5 cm in 83%, change in signal intensity from homogenous on T1-weighted images to heterogenous on T2-weighted images in 74%, irregular margins in 74%, and heterogenous contrast enhancement in 91%. The accuracy of these features was 76%, 58%, 78%, and 60%, respectively. Most benign and malignant lesions were intramuscular in location. A significant number (38%) of benign lesions were located in the intermuscular facial plane. Definitive diagnosis was made in 42% of the lesions. CONCLUSIONS MRI is an excellent modality for evaluating soft tissue neoplasms; however, prediction of a specific diagnosis and differentiation of malignant and benign lesions is not always possible.
Collapse
Affiliation(s)
- J Sen
- Department of Radiodiagnosis, Pt. B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana- 124001, India
| | | | | | | | | |
Collapse
|
130
|
Tandon A, Gulleria K, Gupta S, Goel S, Bhargava SK, Vaid NB. Mature ovarian dermoid cyst invading the urinary bladder. Ultrasound Obstet Gynecol 2010; 35:751-753. [PMID: 20069670 DOI: 10.1002/uog.7524] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Mature ovarian dermoid cysts are common lesions, accounting for up to 10-25% of all ovarian neoplasms. Uncomplicated dermoid cysts are often asymptomatic and are relatively easy to diagnose on imaging and to treat. Symptoms develop once complications set in and these may cause diagnostic dilemmas. Torsion (16%) is the most common complication, while rupture, suppuration and malignant transformation are relatively uncommon. Of all these complications, spontaneous rupture into the urinary bladder is least common. The diagnosis of this condition has been through the use of cystoscopy or laparotomy in all cases reported so far. We report a case of a 30-year-old patient with pyuria and dysuria, where ultrasound examination clearly demonstrated an ovarian dermoid cyst invading the urinary bladder. A clear-cut imaging diagnosis helped to allow planning of surgery in advance and a mucosa-sparing partial bladder resection could be performed.
Collapse
Affiliation(s)
- A Tandon
- Department of Radiology & Imaging, University College of Medical Sciences and Guru Tegh Bahadur Hospital, Dilshad Garden, Delhi, India
| | | | | | | | | | | |
Collapse
|
131
|
Schinke C, Goel S, Bhagat TD, Zhou L, Mo Y, Gallagher R, Kabalka GW, Platanias LC, Verma A, Das B. Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia. Leuk Lymphoma 2010; 51:1108-14. [PMID: 20536349 PMCID: PMC4104194 DOI: 10.3109/10428191003786766] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The binding of all-trans retinoic acid (ATRA) to retinoid receptor-alpha (RAR-alpha) relieves transcriptional repression induced by the promyelocytic leukemia-retinoic acid receptor (PML-RAR) oncoprotein. The ATRA molecule contains a cyclohexenyl ring, a polyene chain containing conjugated double alkene bonds, and a terminal carboxyl group. To determine the contributions of these structural components of ATRA to its clinical efficacy, we synthesized three novel retinoids. These consisted of either a modified conjugated alkene backbone with an intact acid moiety (13a) or a modified conjugated alkene backbone and conversion of the acid group to either an ester (13b) or an aromatic amide (13c). Reporter assays demonstrated that compound 13a successfully relieved transcriptional repression by RAR-alpha, while 13b and 13c could not, demonstrating the critical role of the acid moiety in this binding. However, only ATRA was able to significantly inhibit the proliferation of APL cells while 13a, 13b, or 13c was not. Furthermore, only 13a led to partial non-significant differentiation of NB4 cells, demonstrating the importance of C9-C10 double bonds in differentiation induced CD11 expression. Our results demonstrate that both the acid moiety and conjugated double bonds present in the ATRA molecule are important for its biological activity in APL and have important implications for the design of future novel retinoids.
Collapse
Affiliation(s)
| | - Swati Goel
- Albert Einstein College of Medicine, Bronx, NY, USA
| | | | - Li Zhou
- Albert Einstein College of Medicine, Bronx, NY, USA
| | - Yongkai Mo
- Albert Einstein College of Medicine, Bronx, NY, USA
| | | | | | - Leonidas C. Platanias
- Northwestern University School of Medicine and Jesse Brown VA Medical Center, Chicago, IL, USA
| | - Amit Verma
- Albert Einstein College of Medicine, Bronx, NY, USA
| | - Bhaskar Das
- Albert Einstein College of Medicine, Bronx, NY, USA
| |
Collapse
|
132
|
Lin C, Ghamande SA, Dezube BJ, Silverman MH, Fong K, Kuo M, Mach W, Tseng Y, Hsu S, Goel S. TLC388, a novel topoisomerase-1 inhibitor with antihypoxia inducible factor-1 alpha activity: A phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
133
|
Basu Mallick A, Seetharam R, Sood A, Mariadason J, Goel S. Evaluation of inducible expression of ERCC1 as a biomarker of drug response in human colorectal cancer cell lines. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
134
|
Swami U, Petrylak DP, Raftopoulos H, Shuster DE, Wang G, Kumar V, Martinez G, Goel S, Aisner J. Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2589] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
135
|
Chaudhary I, Rajdev L, Swami U, Wilhelm F, Cohen B, Haigentz M, Kaubisch A, Goel S, Mani S, Ghalib MH. Phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13133] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
136
|
Sood A, McClain D, Seetharam R, Al-rahamneh M, Kaubisch A, Rajdev L, Tanaka K, Mariadason J, Goel S. Beyond KRAS: The quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3567] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
137
|
|
138
|
Goel S, Bommireddipalli S, DePuey EG. Effect of Proton Pump Inhibitors and H2 Antagonists on the Stomach Wall in 99mTc-Sestamibi Cardiac Imaging. J Nucl Med Technol 2009; 37:240-3. [DOI: 10.2967/jnmt.109.065847] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
139
|
Seetharam R, Sood A, Goel S. Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance. Ecancermedicalscience 2009; 3:153. [PMID: 22276017 PMCID: PMC3224005 DOI: 10.3332/ecancer.2009.153] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2009] [Indexed: 12/31/2022] Open
Abstract
Oxaliplatin is a third-generation platinum compound that has shown a wide range of anti-tumour activity in metastatic cancer and in multiple cell lines. It contains a diaminocyclohexane carrier ligand and is one of the least toxic platinum agents. In the past decade, the use of oxaliplatin for the treatment of colorectal cancer has become increasingly popular because neither cisplatin nor carboplatin demonstrate significant activity. Similar to cisplatin, oxaliplatin binds to DNA, leading to GG intra-strand crosslinks. Oxaliplatin differs from its parent compounds in its mechanisms of action, cellular response and development of resistance, which are not fully understood. Like most chemotherapeutic agents, efficacy of oxaliplatin is limited by the development of cellular resistance. ERCC1 (excision repair cross-complementation group 1) mediated nucleotide excision repair pathway appears to be the major pathway involved in processing oxaliplatin, because the loss of mismatch repair does not lead to oxaliplatin resistance. Recent findings support the involvement of many genes and different pathways in developing oxaliplatin resistance. This mini-review focuses on the effects of oxaliplatin treatment on cell lines with special emphasis on colorectal cell lines.
Collapse
Affiliation(s)
- Rn Seetharam
- Department of Oncology, Montefiore Medical Center/Albert Einstein Cancer Center, 111 E 210th St, Bronx, NY 10467, USA
| | | | | |
Collapse
|
140
|
Bellairs V, Bellairs R, Goel S. Studies on an Indian polydesmoid millipede Streptogonopus phipsoni Life cycle and swarming behaviour of the larvae. J Zool (1987) 2009. [DOI: 10.1111/j.1469-7998.1983.tb06115.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
141
|
Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2:36. [PMID: 19674465 PMCID: PMC2736171 DOI: 10.1186/1756-8722-2-36] [Citation(s) in RCA: 317] [Impact Index Per Article: 21.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2009] [Accepted: 08/12/2009] [Indexed: 12/17/2022] Open
Abstract
Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the neurologic side effects of sedation and neuropathy and has emerged as a drug with activity against various hematological and solid malignancies. It is approved by FDA for clinical use in myelodysplastic syndromes with deletion of chromosome 5q and multiple myeloma. Lenalidomide has been shown to be an immunomodulator, affecting both cellular and humoral limbs of the immune system. It has also been shown to have anti-angiogenic properties. Newer studies demonstrate its effects on signal transduction that can partly explain its selective efficacy in subsets of MDS. Even though the exact molecular targets of lenalidomide are not well known, its activity across a spectrum of neoplastic conditions highlights the possibility of multiple target sites of action.
Collapse
Affiliation(s)
- Venumadhav Kotla
- Department of Medicine, Albert Einstein College of Medicine, Bronx, USA.
| | | | | | | | | | | | | |
Collapse
|
142
|
Ghalib MH, Desai KK, Gollamudi R, Chaudhary I, Einstein M, Coffey M, Mettinger K, Mani S, Goel S. Dose escalation and pharmacodynamic study of intravenous adminstration of Reolysin, a live replication competent RNA virus in patients with advanced solid tumors. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3583 Background: Reolysin is reovirus serotype 3 - Dearing strain, a double-stranded replication- competent RNA non-enveloped icosahedral virus. It induces cytopathic and anti-cancer effects in cells with an activating mutation in the ras proto-oncogene. Methods: This was a single center dose escalation trial of Reolysin administered intravenously every four weeks in doses ranging from 1X108 to 3X1010 tissue culture infective dose (TCID)50. Serum for neutralizing antibody, and serum, stool, saliva, and urine for viral shedding were collected. Tumor samples were analyzed for activating mutations in the ras and braf oncogenes. Results: Eighteen patients received 27 doses of Reolysin in 6 dose cohorts accomplishing a 300 fold dose escalation without a protocol-defined dose limiting toxicity. Drug related grade 2 toxicities included fatigue and fever (1 patient each). All patients developed neutralizing antibody during the course of the study. Viral shedding was observed in 6 patients [urine (5), serum (4), saliva (3), and stool (2)]. One patient with anthracycline and taxane refractory breast cancer experienced a partial response (PR) and her tumor had a mutation in the ras oncogene. Biopsy from a chest wall mass showed evidence of necrosis and viral replication by electron microscopy. The overall clinical benefit rate was 45% and appeared higher in patients with viral shedding (67%) than those without (33%). Conclusions: Reolysin administered as a one hour infusion on a monthly schedule is safe and well-tolerated even in multiple doses. Reolysin has anti-tumor activity as a single agent warranting further evaluation, including in combination with chemotherapy. Viral shedding may suggest intrapatient replication yielding a benefit and should be studied carefully in future studies. [Table: see text]
Collapse
Affiliation(s)
- M. H. Ghalib
- Montefiore Medical Center, Bronx, NY; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - K. K. Desai
- Montefiore Medical Center, Bronx, NY; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - R. Gollamudi
- Montefiore Medical Center, Bronx, NY; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - I. Chaudhary
- Montefiore Medical Center, Bronx, NY; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - M. Einstein
- Montefiore Medical Center, Bronx, NY; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - M. Coffey
- Montefiore Medical Center, Bronx, NY; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - K. Mettinger
- Montefiore Medical Center, Bronx, NY; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - S. Mani
- Montefiore Medical Center, Bronx, NY; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - S. Goel
- Montefiore Medical Center, Bronx, NY; Oncolytics Biotech Inc., Calgary, AB, Canada
| |
Collapse
|
143
|
Jung G, Knight D, Moadel A, Desai K, Chaudhary I, Gajavelli S, Ghalib MH, Mani S, Goel S. Assessment of quality of life using FACT-G survey in a phase I trial in cancer patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20709 Background: Quality of life (QoL) assessment in clinical trials has been gaining more attention. FACT-G surveys have been validated to assess QoL in clinical trials involving oncology patient (Cella DF et al, J Clin Oncol 11:570–579, 1993). However, there is paucity of evaluation of QoL in patients with advanced cancer participating in Phase I clinical trials. Methods: FACT-G surveys were conducted within the context of a Phase I trial to identify a safe dose and potential drug-drug interations of capecitabine and irinotecan combination (Goel, S et al, Invest New Drugs 25:237–245, 2007). The FACT-G survey consists of 28 questions in 5 sections, namely, physical well-being, social/family well-being, emotional well-being, relationship with doctor, and functional well-being). Patients were requested to complete the FACT-G surveys at baseline and every two cycles thereafter (each cycle of 3 weeks duration). Results: Forty-one of 47 patients with advanced solid tumors who participated in the clinical trial completed FACT-G surveys. Mean scores were calculated for each time point. The mean QoL scores at baseline and post cycle 2 were 53 and 58, respectively (p = 0.1). Post cycle 4, the mean QoL score was 62 [p = 0.01, (vs. baseline)]. Following cycle 4, the number of respondents decreased to the extent where we were unable to ascertain any further changes in the QoL scores. Conclusions: It is feasible to use FACT-G survey as a tool to assess QoL in patients participating in an oncology phase I clinical trial. Although the sample size of the patient population was not powered for any statistical significance, there was a trend toward improving QoL based on FACT-G survey scores. This suggests that phase I clinical trials may provide improvement of QoL for some patients. FACT-G is a useful tool in assessing QoL in oncology phase I trial study population. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- G. Jung
- Montefiore Medical Center, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY
| | - D. Knight
- Montefiore Medical Center, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY
| | - A. Moadel
- Montefiore Medical Center, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY
| | - K. Desai
- Montefiore Medical Center, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY
| | - I. Chaudhary
- Montefiore Medical Center, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY
| | - S. Gajavelli
- Montefiore Medical Center, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY
| | - M. H. Ghalib
- Montefiore Medical Center, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY
| | - S. Mani
- Montefiore Medical Center, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY
| | - S. Goel
- Montefiore Medical Center, Bronx, NY; Albert Einstein College of Medicine, Bronx, NY
| |
Collapse
|
144
|
Mita AC, Sankhala K, Sarantopoulos J, Carmona J, Okuno S, Goel S, Chugh R, Coffey MC, Mettinger K, Mita MM. A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10524] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10524 Background: Reolysin is a Dearing strain, naturally occurring, ubiquitous human reovirus. The PKR (double stranded RNA-activated protein kinase) is inhibited and therefore the virus replicates specifically in transformed cells possessing an activated Ras pathway producing lysis. In vitro and in vivo studies with Reolysin in sarcoma cell lines revealed significant antitumor activity. Methods: This phase II open-label, single agent study was designed to characterize the efficacy and safety of Reolysin given IV every 28 days in patients (pts) with bone or soft tissue sarcoma with lung metastasis using a Simon two-stage design. 38 pts were accrued to the first stage. If 1 or more pts experience clinical benefit (prolonged SD > 6 months, partial or complete response) up to 52 pts could be accrued. The agent will be considered active if 3 or more responses or prolonged SD are observed. Results: Since July 2007, 43 pts age 19–76 (median 49) were enrolled (20 female) and received a total of 141 cycles (range 1–18). All pts had performance status 1 (29 pts) or 0 (14 pts). 38 pts received prior chemotherapy, radiotherapy, biological agents or combinations for their metastatic disease, 15 pts received more than 3 chemotherapy regimens. The sarcoma subtypes included: synovial sarcoma (13 pts), osteosarcoma (7 pts), leiomyosarcoma (7 pts), MFH (5 pts), Ewing/PNET (1 pt), chordoma (1 pt), others (9 pts). Side effects were mild to moderate (grade 1–2) and included constitutional symptoms fever, chills, fatigue. Two pts experienced respiratory side effects (cough and dyspnea) and 2 pts had diarrhea. Hematological side effects included grade 2–3 neutropenia (6 pts) and grade 2 thrombocytopenia (2 pts). One patient experienced grade 2 AST elevation. 33 pts are evaluable for response to date: 14 pts (42%) had SD for 2+ months including 5 pts having SD for more than 6 months. Conclusions: Utilization of single agent reovirus for treatment of sarcoma is a novel and unique therapeutic approach to date. Reolysin is well tolerated and shows promise for the treatment of metastatic sarcoma. Primary efficacy goals have been met. Accrual is ongoing to a total of 52 pts. [Table: see text]
Collapse
Affiliation(s)
- A. C. Mita
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - K. Sankhala
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - J. Sarantopoulos
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - J. Carmona
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - S. Okuno
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - S. Goel
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - R. Chugh
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - M. C. Coffey
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - K. Mettinger
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - M. M. Mita
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| |
Collapse
|
145
|
Goel S, Goldberg GL, Kuo DYS, Muggia F, Arezzo J, Mani S. Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone. Ann Oncol 2008; 19:2048-52. [PMID: 18644829 DOI: 10.1093/annonc/mdn420] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND We have previously established the recommended phase II dose (RPTD) of ixabepilone as 40 mg/m(2) administered over 1 h repeated every 3 weeks with neuropathy as a cumulative dose-limiting toxicity. We expanded the cohort at the RPTD to include detailed assessment of nerve damage in these patients. We report our findings on vibration perception threshold (VPT) and neuropathy. PATIENTS AND METHODS Forty-four patients were treated with a median (range) of three (1-14) cycles of ixabepilone. The VPT (5-min duration) and nerve conduction test (NCT, 10-min duration) were carried out in the office, before ixabepilone dosing, and every two cycles thereafter. RESULTS Neuropathy (grade 1 and grades 2-3) was observed in 17 (38.6%) and 11 (25%) patients, respectively. The mean increase in VPT as a function of grade 0-1 versus grades 2-3 neuropathy was 0.235 +/- 0.03 versus 0.869 +/- 0.09 (P = 0.049) vibration units. The F-wave frequency and distal motor latency, as assessed using the NCT, did not correlate with clinical neurotoxicity. CONCLUSION The change in VPT is observed early and likely reflects early vibration perception change. Mean change in VPT correlates with the severity of clinical neuropathy. Whether VPT change predicts onset of severe neuropathy warrants prospective testing and validation.
Collapse
Affiliation(s)
- S Goel
- Department of Oncology, Albert Einstein College of Medicine and Cancer Center, Bronx, NY, USA.
| | | | | | | | | | | |
Collapse
|
146
|
Vainshtein JM, Ghalib MH, Kumar M, Chaudhary I, Maniar M, Taft DR, Cosenza S, Reddy EP, Goel S, Mani S. Phase I study of ON 01910.Na, a novel polo-like kinase 1 pathway modulator, administered as a weekly 24-hour continuous infusion in patients with advanced cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2515] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
147
|
Goel S, Simes RJ, Beith JM. An exploratory analysis of cardiac biomarkers in women receiving trastuzumab. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
148
|
Guo Z, Wheler JJ, Naing A, Mani S, Goel S, Mulcahy M, Gamza F, Longley C, Buchbinder A, Kurzrock R. Clinical pharmacokinetics (PK) of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies: A phase I, first-in-human, dose-escalation study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2556] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
149
|
Dilawari A, Goel S, Assal A, Moore S, Muggia FM, Mani S. Ixabepilone (Ixa) in taxane-pretreated women with breast and gynecologic cancers: Overall tolerance, neurotoxicity (NT) assessment and evidence of activity. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.16529] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
150
|
Gollamudi R, Wong BM, Ghalib MH, Kumar M, Desai K, Chaudhary I, Goel S, Mani S. Clinical benefits and risks of phase I oncology trials: experience from a single institution. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.6572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|